Quipt Home Medical Receives Buyout Proposal from Forager Capital at 120% Premium
ByAinvest
Monday, Aug 25, 2025 9:10 am ET1min read
QIPT--
Quipt Home Medical, which provides durable and home medical equipment and supplies in the United States, has seen its target price lifted by Canaccord Genuity Group from $1.70 to $2.30 [1]. The company has a consensus rating of "Moderate Buy" and an average target price of $3.15 among analysts [1].
Forager Capital, which holds 9.7% of Quipt Home Medical, submitted a fully financed proposal to acquire all outstanding shares for $3.10 per share [4]. The proposal includes a go-shop provision, allowing the board to seek superior offers after signing the deal. Forager believes its Acquisition Proposal delivers immediate and certain value to all shareholders [4].
The acquisition proposal is not subject to financing or due diligence and can be executed immediately [2]. Quipt Home Medical's shares have seen significant institutional interest, with large investors such as Geode Capital Management LLC, Wells Fargo & Company MN, and Northern Trust Corp increasing their stakes in the company [1].
References:
[1] https://www.marketbeat.com/instant-alerts/quipt-home-medical-nasdaqqipt-price-target-raised-to-230-at-canaccord-genuity-group-2025-08-19/
[2] https://seekingalpha.com/news/4488726-forager-capital-proposes-buyout-of-quipt-home-medical-shares-up-22
[3] https://www.marketscreener.com/news/quipt-home-medical-shareholder-forager-capital-makes-another-buyout-bid-ce7c50d8d88ef022
[4] https://www.nasdaq.com/press-release/forager-capital-management-submits-fully-financed-proposal-acquire-quipt-home-medical
Forager Capital has proposed a buyout of Quipt Home Medical, offering $3.10 per share in cash, a 120% premium over the company's unaffected price of $1.41 as of May 19. The offer represents a 22% increase in Quipt's shares, and the proposal is not subject to due diligence.
Forager Capital has proposed a buyout of Quipt Home Medical (NASDAQ: QIPT), offering $3.10 per share in cash. This represents a 120% premium over the company's unaffected price of $1.41 as of May 19, 2025 [2]. The offer, which is not subject to due diligence, has led to a 22% increase in Quipt's shares, with shares trading up to $2.15 on Tuesday [1].Quipt Home Medical, which provides durable and home medical equipment and supplies in the United States, has seen its target price lifted by Canaccord Genuity Group from $1.70 to $2.30 [1]. The company has a consensus rating of "Moderate Buy" and an average target price of $3.15 among analysts [1].
Forager Capital, which holds 9.7% of Quipt Home Medical, submitted a fully financed proposal to acquire all outstanding shares for $3.10 per share [4]. The proposal includes a go-shop provision, allowing the board to seek superior offers after signing the deal. Forager believes its Acquisition Proposal delivers immediate and certain value to all shareholders [4].
The acquisition proposal is not subject to financing or due diligence and can be executed immediately [2]. Quipt Home Medical's shares have seen significant institutional interest, with large investors such as Geode Capital Management LLC, Wells Fargo & Company MN, and Northern Trust Corp increasing their stakes in the company [1].
References:
[1] https://www.marketbeat.com/instant-alerts/quipt-home-medical-nasdaqqipt-price-target-raised-to-230-at-canaccord-genuity-group-2025-08-19/
[2] https://seekingalpha.com/news/4488726-forager-capital-proposes-buyout-of-quipt-home-medical-shares-up-22
[3] https://www.marketscreener.com/news/quipt-home-medical-shareholder-forager-capital-makes-another-buyout-bid-ce7c50d8d88ef022
[4] https://www.nasdaq.com/press-release/forager-capital-management-submits-fully-financed-proposal-acquire-quipt-home-medical

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet